SOPHiA GENETICS | Opts for Nasdaq IPO
Share this article
Closing of $234 mio. Initial Public Offering & $20 mio. Private Placement
SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine, announced the closing of its initial public offering of 13’000’000 ordinary shares at a price of $18 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated fees and offering expenses payable by SOPHiA GENETICS SA, are $234 million. In addition, SOPHiA GENETICS SA has granted the underwriters an option to purchase up to 1’950’000 additional ordinary shares at the initial public offering price, less underwriting discounts and commissions. The ordinary shares began trading on the Nasdaq Global Select Market on July 23, 2021 under the symbol “SOPH.”
In addition, SOPHiA GENETICS SA announced the closing of a private placement, in which it issued and sold 1’111’111 ordinary shares to an affiliate of GE Healthcare. The gross proceeds from the private placement, before deducting estimated expenses payable by SOPHiA GENETICS SA, are $20 million. The sale of ordinary shares in the private placement was made pursuant to an exemption from the registration requirements of the U.S. Securities Act of 1933, as amended.